Abstracts tagged "COVID-19"

Abstract Number: 1928 • ACR Convergence 2023
Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Cristina Calomarde Gomez¹, Raquel Ugena García¹, Julia Valera², Melisa Mena², Maria Esteve², Irma Casas², jose Antonio Dominguez-Benitez², lidia Carabias-Ane², isaac Nuño-Ruiz², Cristina ramo-Tello², Javier Santesmases², Lourdes Mateo Soria³ and Melania Martinez Morillo¹, ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³HOSPITAL GERMANS TRIAS I PUJOL, Badalona, Spain
Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…
Abstract Number: 2511 • ACR Convergence 2023
Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies
Christian Ammitzbøll¹, Marianne Kragh Thomsen², Lars Erik Bartels¹, Marie-Louise From Hermansen¹, Mathias Hänel³, Rasmus Klose-Jensen¹, Mads Christian Lamm Larsen¹, Cecile Bo Hansen⁴, Morgan Oliver Lauritsen¹, Susan Mikkelsen⁵, Clara Mistegaard¹, Morten Aagaard Nielsen¹, Esben Naeser¹, Janne Bille Mønster Olesen⁵, Peter Garred⁴, Christian Erikstrup⁵, Ellen-Margrethe Hauge⁶ and Anne Troldborg⁶, ¹Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, ⁴Clinical Immunology, sect. 7631, Rigshospitalet, Copenhagen, Denmark, ⁵Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, ⁶Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rituximab (RTX) treatment significantly decreases the antibody response to COVID-19 vaccines, raising concerns about its use. However, unlike during the pandemic, most patients initiating…
Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Greta Mastrangelo¹, Ellen Go², Paul Tsoukas², Hua Lu³, Amy Xu², Arthur Hoi Hin Cheng² and Rae Yeung⁴, ¹The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, ²The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
Abstract Number: 035 • 2023 Pediatric Rheumatology Symposium
SARS-CoV-2 Vaccination of Children with a History of Multisystem Inflammatory Syndrome
Mariana Sanchez Villa¹, Matthew Wisniewski¹, Jessica Nguyen¹, Eyal Muscal¹, Marietta Deguzman², Sara Kristen Sexson Tejtel¹, Sridevi Devaraj¹, Flor Munoz-Rivas¹, Leila Sahni¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Most children who contract SARS-CoV-2 are asymptomatic or mildly symptomatic, but a subset subsequently develop the hyperinflammatory condition called multisystem inflammatory syndrome in children…
Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium
COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey
Beth Rutstein¹, Merav Heshin Bekenstein², Maria Schletzbaum³, Nora Singer⁴, Rebecca Sadun⁵, Melanie Kohlheim⁶, Vincent Del Gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock⁹, Monica Ardura⁸, Vidya Sivaraman¹⁰ and For the CARRA Investigators¹¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Metro Health, Cleveland, OH, ⁵Duke University, Durham, NC, ⁶None, Columbus, OH, ⁷CARRA, Washington, DC, ⁸Nationwide Children's Hospital, Columbus, OH, ⁹The Ohio State University, Columbus, OH, ¹⁰Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…
Abstract Number: 070 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies
Dawn Wahezi¹, Dominique Jerome¹, Evin Rothschild¹, Jeffrey Dvergsten², Stacey Tarvin³, Susan Kim⁴ and Tamar Rubinstein¹, ¹Children's Hospital at Montefiore, New York, NY, ²Duke University Hospital, Durham, NC, ³Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Since the onset of the COVID-19 pandemic, there have been concerns regarding the risks of SARS-CoV-2 infection in patients with juvenile idiopathic inflammatory myopathies…
Abstract Number: 076 • 2023 Pediatric Rheumatology Symposium
COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Brooke Rezmer¹, Michelle Adler², Tamar Rubinstein³, Andrea Knight⁴ and Natoshia Cunningham⁵, ¹Michigan State University College of Human Medicine, Grand Rapids, MI, ²Michigan State University, East Lansing, ³Children's Hospital at Montefiore, New York, NY, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Michigan State University, Grand Rapids, MI
Background/Purpose: Psychological symptoms are common in childhood-onset systemic lupus erythematosus (cSLE) and may impact other psychological and health-related outcomes. Mental health problems such as anxiety…
Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Rebecca Hetrick¹, Maria Pereira² and Marietta De Guzman³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
Abstract Number: 097 • 2023 Pediatric Rheumatology Symposium
Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease
Mariana Correia Marques¹, Paul Subrata², Carol Lake³, Ly-Lan Bergeron⁴, Rashmi Sinha⁵, Luciana Peixoto⁶, Marinka Twilt⁷ and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases/Children`s National Hospital, Bethesda, MD, ²NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³NIH, GAITHERSBURG, MD, ⁴NIH/NIAMS, Vienna, VA, ⁵Systemic JIA Foundation, Cincinnati, OH, ⁶Systemic JIA Foundation, Cincinnati, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD
Background/Purpose: Immunization is one of the most important tools for the control of the Covid-19 pandemic. The safety and effectiveness of the Covid-19 immunizations have…
Abstract Number: 099 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis
Tresa Ambooken¹, Sangati Kadakia¹, Tara Lozy¹, Brianna Bulbin², Suhas Ganguli³, Dawn Wahezi⁴ and Sivia Lapidus¹, ¹Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Hackensack Meridian School of Medicine, Hackensack, NJ, ³Department of Pediatrics, K. Hovnanian Children's Hospital, Jersey Shore University Medical Center, Neptune City, NJ, ⁴Children's Hospital at Montefiore, New York, NY
Background/Purpose: Juvenile Dermatomyositis (JDM) is theorized to occur in a genetically susceptible individual as a response to an environmental trigger, leading to autoimmunity and inflammation.…
Abstract Number: 105 • 2023 Pediatric Rheumatology Symposium
Awareness of Multisystem Inflammatory Syndrome in Children Among U.S. Parents: A Cross-Sectional Survey
Lyndsey Cole¹, E. Adrianne Hammershaimb², Yuanyuan Liang², Megan Hendrich³, Dhiman Das³, Robert Petrin³, James Campbell², Sean O'Leary¹ and Jessica Cataldi¹, ¹University of Colorado School of Medicine, Denver, CO, ²University of Maryland School of Medicine, Baltimore, MD, ³Ipsos US Public Affairs, Washington, DC
Background/Purpose: Little is known about parental awareness of multisystem inflammatory syndrome in children (MIS-C), a rare but severe sequela of SARS-CoV-2 infection. We sought to…
Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 117 • 2023 Pediatric Rheumatology Symposium
A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children
Alexis Begezda, Penn State, State College, PA
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…
Abstract Number: 128 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions
Paul Tsoukas¹, Hua Lu², Marla Mendes de Aquino², Michael Ombrello³, Lisa Strug² and Rae Yeung⁴, ¹The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a novel clinical entity presenting following SARS CoV2 infection. This study describes a subgroup of MIS-C patients…
Abstract Number: L08 • ACR Convergence 2022
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Christopher Podgorski¹ and Deborah Parks², ¹BJC/Washington University Consortium, St. Louis, MO, ²Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The…

« Previous Page
1
…
8
9
10
11
12
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].